KR102728491B1 - 전장 고분자량 키니노겐(hmwk) 및 절단된 hmwk를 구별하기 위한 펩타이드 정량화 검정법 - Google Patents

전장 고분자량 키니노겐(hmwk) 및 절단된 hmwk를 구별하기 위한 펩타이드 정량화 검정법 Download PDF

Info

Publication number
KR102728491B1
KR102728491B1 KR1020187020049A KR20187020049A KR102728491B1 KR 102728491 B1 KR102728491 B1 KR 102728491B1 KR 1020187020049 A KR1020187020049 A KR 1020187020049A KR 20187020049 A KR20187020049 A KR 20187020049A KR 102728491 B1 KR102728491 B1 KR 102728491B1
Authority
KR
South Korea
Prior art keywords
hmwk
peptide
seq
sample
glu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020187020049A
Other languages
English (en)
Korean (ko)
Other versions
KR20180134838A (ko
Inventor
지앙 우
궈동 장
다니엘 제이. 섹스톤
라이언 파우셋
굴 엠. 무사타파
마크 즈젝
Original Assignee
다케다 파머수티컬 컴패니 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 다케다 파머수티컬 컴패니 리미티드 filed Critical 다케다 파머수티컬 컴패니 리미티드
Priority to KR1020247036874A priority Critical patent/KR102874711B1/ko
Publication of KR20180134838A publication Critical patent/KR20180134838A/ko
Application granted granted Critical
Publication of KR102728491B1 publication Critical patent/KR102728491B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/8139—Cysteine protease (E.C. 3.4.22) inhibitors, e.g. cystatin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/62—Detectors specially adapted therefor
    • G01N30/72—Mass spectrometers
    • G01N30/7233—Mass spectrometers interfaced to liquid or supercritical fluid chromatograph
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N2030/022—Column chromatography characterised by the kind of separation mechanism
    • G01N2030/027—Liquid chromatography
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
    • G01N2030/8813—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials
    • G01N2030/8831—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials involving peptides or proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2560/00—Chemical aspects of mass spectrometric analysis of biological material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/22—Haematology
    • G01N2800/224—Haemostasis or coagulation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Enzymes And Modification Thereof (AREA)
KR1020187020049A 2015-12-15 2016-12-15 전장 고분자량 키니노겐(hmwk) 및 절단된 hmwk를 구별하기 위한 펩타이드 정량화 검정법 Active KR102728491B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020247036874A KR102874711B1 (ko) 2015-12-15 2016-12-15 전장 고분자량 키니노겐(hmwk) 및 절단된 hmwk를 구별하기 위한 펩타이드 정량화 검정법

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562267734P 2015-12-15 2015-12-15
US62/267,734 2015-12-15
PCT/US2016/066936 WO2017106504A1 (en) 2015-12-15 2016-12-15 Peptide quantitation assay for differentiating full-length high molecular weight kininogen (hmwk) and cleaved hmwk

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020247036874A Division KR102874711B1 (ko) 2015-12-15 2016-12-15 전장 고분자량 키니노겐(hmwk) 및 절단된 hmwk를 구별하기 위한 펩타이드 정량화 검정법

Publications (2)

Publication Number Publication Date
KR20180134838A KR20180134838A (ko) 2018-12-19
KR102728491B1 true KR102728491B1 (ko) 2024-11-13

Family

ID=57794352

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020187020049A Active KR102728491B1 (ko) 2015-12-15 2016-12-15 전장 고분자량 키니노겐(hmwk) 및 절단된 hmwk를 구별하기 위한 펩타이드 정량화 검정법
KR1020247036874A Active KR102874711B1 (ko) 2015-12-15 2016-12-15 전장 고분자량 키니노겐(hmwk) 및 절단된 hmwk를 구별하기 위한 펩타이드 정량화 검정법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020247036874A Active KR102874711B1 (ko) 2015-12-15 2016-12-15 전장 고분자량 키니노겐(hmwk) 및 절단된 hmwk를 구별하기 위한 펩타이드 정량화 검정법

Country Status (13)

Country Link
US (3) US11668718B2 (https=)
EP (2) EP3390439B1 (https=)
JP (4) JP7092669B2 (https=)
KR (2) KR102728491B1 (https=)
CN (1) CN108602877A (https=)
AU (3) AU2016372159B2 (https=)
CA (1) CA3008621A1 (https=)
CO (1) CO2018007216A2 (https=)
EA (1) EA201891414A1 (https=)
IL (4) IL312919B2 (https=)
MX (2) MX2018007493A (https=)
NZ (1) NZ743482A (https=)
WO (1) WO2017106504A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6757252B2 (ja) 2013-10-21 2020-09-16 ダイアックス コーポレーション 血漿カリクレイン系バイオマーカーを決定するためのアッセイ
CA2927695C (en) 2013-10-21 2022-03-01 Dyax Corp. Diagnosis and treatment of autoimmune diseases
KR20240133761A (ko) 2015-10-19 2024-09-04 다케다 파머수티컬 컴패니 리미티드 절단된 고분자량 키니노겐의 검출을 위한 면역검정법
EP3390439B1 (en) 2015-12-15 2025-03-12 Takeda Pharmaceutical Company Limited Peptide quantitation assay for differentiating full-length high molecular weight kininogen (hmwk) and cleaved hmwk
WO2018225830A1 (ja) * 2017-06-08 2018-12-13 国立大学法人宮崎大学 肺がんの検出方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5047323A (en) * 1986-01-22 1991-09-10 Temple University Of The Commonwealth System Of Higher Education Method for detecting human kininogen using monoclonal antibodies thereto
JP2603487B2 (ja) 1987-11-26 1997-04-23 大日本製薬株式会社 ガンに罹患している疑いのあるヒトをスクリーニングする方法
JPH08208692A (ja) 1994-09-28 1996-08-13 Sumitomo Pharmaceut Co Ltd 新規な細胞接着抑制ペプチド誘導体
JP3073439B2 (ja) * 1996-02-08 2000-08-07 雪印乳業株式会社 骨形成促進及び骨吸収防止剤
EP1044012B1 (en) 1998-11-10 2006-05-03 Temple University of the Commonwealth System of Higher Education Inhibition of angiogenesis by peptide analogs of high molecular weight kininogen domain 5
US20060154319A1 (en) 1999-04-29 2006-07-13 Flodgaard Hans J Inhibition of bradykinin release
WO2001034195A1 (en) 1999-11-12 2001-05-17 Temple University Of The Commonwealth System Of Higher Education Inhibition of angiogenesis by antibodies against high molecular weight kininogen domain 5
CA2478962A1 (en) 2002-03-15 2003-09-25 Attenuon, Llc Cell surface tropomyosin as a target of angiogenesis inhibition
CN1858243A (zh) 2005-04-30 2006-11-08 安徽省生物医学研究所 一种预测血管紧张素ii受体拮抗剂类降压药药物作用的方法及其应用
EP2216651A4 (en) * 2007-10-18 2010-12-01 Miyazaki Prefectural Ind Suppo BIOMARKERS FOR THE DIAGNOSIS OF LIVER DISEASE
AU2009269257A1 (en) 2008-07-07 2010-01-14 Nippon Zoki Pharmaceutical Co., Ltd. Method for detection of fibromyalgia
GB0821721D0 (en) 2008-11-27 2008-12-31 Hansa Medical Ab Antimicrobial therapy
ES2529101T3 (es) 2009-03-30 2015-02-16 Nordic Bioscience A/S Ensayo de biomarcadores para fibrosis
JP5714285B2 (ja) 2010-09-29 2015-05-07 株式会社プロトセラ 妊娠高血圧症候群マーカーおよびそれを用いた診断
CN102558329A (zh) 2010-12-10 2012-07-11 中国人民解放军军事医学科学院生物医学分析中心 一组特异性多肽及其在制备肺癌早期诊断试剂中的用途
RS57413B1 (sr) 2012-03-28 2018-09-28 Sanofi Sa Antitela za ligande bradikinin b1 receptora
WO2014113712A1 (en) * 2013-01-20 2014-07-24 Dyax Corp. Evaluation and treatment of bradykinin-mediated disorders
JP2016188761A (ja) 2013-08-23 2016-11-04 国立研究開発法人国立国際医療研究センター 糖尿病腎症の発症または発症リスクの検出方法及びキット
JP6757252B2 (ja) 2013-10-21 2020-09-16 ダイアックス コーポレーション 血漿カリクレイン系バイオマーカーを決定するためのアッセイ
WO2015120036A1 (en) * 2014-02-04 2015-08-13 University Of Virginia Patent Foundation Compositions and methods for analysis of protein sequences and post-translational modifications
CN104155457B (zh) 2014-08-22 2016-11-16 北京蛋白质组研究中心 一种结直肠癌相关“多肽-蛋白组合式标志物”检测试剂盒
CN104345154B (zh) 2014-08-22 2016-10-26 北京蛋白质组研究中心 一种检测多肿瘤相关“多肽-蛋白组合式标志物”的双抗体夹心试剂盒
WO2016081413A1 (en) * 2014-11-17 2016-05-26 The Rockefeller University Compositions and methods for use in diagnosis of alzheimer's disease
EP3390439B1 (en) 2015-12-15 2025-03-12 Takeda Pharmaceutical Company Limited Peptide quantitation assay for differentiating full-length high molecular weight kininogen (hmwk) and cleaved hmwk

Also Published As

Publication number Publication date
JP7425117B2 (ja) 2024-01-30
JP2024026847A (ja) 2024-02-28
JP2019505185A (ja) 2019-02-28
AU2022204058A1 (en) 2022-06-30
NZ743482A (en) 2023-04-28
AU2025200412A1 (en) 2025-02-13
CO2018007216A2 (es) 2018-09-20
WO2017106504A8 (en) 2017-07-13
EP3390439B1 (en) 2025-03-12
US20210025898A1 (en) 2021-01-28
KR20180134838A (ko) 2018-12-19
AU2022204058B2 (en) 2024-10-31
EP4597115A2 (en) 2025-08-06
JP2025188193A (ja) 2025-12-25
IL322971A (en) 2025-10-01
MX2023000773A (es) 2023-02-22
AU2016372159A1 (en) 2018-07-05
WO2017106504A1 (en) 2017-06-22
AU2016372159B2 (en) 2022-03-24
IL259995B2 (en) 2023-05-01
IL312919B2 (en) 2026-02-01
MX2018007493A (es) 2018-09-18
IL259995A (en) 2018-07-31
US20230408528A1 (en) 2023-12-21
US20250172567A1 (en) 2025-05-29
CN108602877A (zh) 2018-09-28
IL297850B2 (en) 2024-10-01
IL259995B1 (en) 2023-01-01
KR102874711B1 (ko) 2025-10-23
JP2022141640A (ja) 2022-09-29
IL312919B1 (en) 2025-10-01
EP3390439A1 (en) 2018-10-24
EA201891414A1 (ru) 2019-02-28
US11668718B2 (en) 2023-06-06
JP7092669B2 (ja) 2022-06-28
EP4597115A3 (en) 2025-08-13
IL297850B1 (en) 2024-06-01
KR20240161708A (ko) 2024-11-12
IL297850A (en) 2023-01-01
JP7758766B2 (ja) 2025-10-22
CA3008621A1 (en) 2017-06-22
BR112018012165A2 (pt) 2018-12-04
IL312919A (en) 2024-07-01
US12135329B2 (en) 2024-11-05

Similar Documents

Publication Publication Date Title
JP7425117B2 (ja) 完全長の高分子量キニノーゲン（ｈｍｗｋ）と切断されたｈｍｗｋとを区別するためのペプチド定量アッセイ
JP2023078232A (ja) 接触系活性化の評価のためのプロテアーゼ阻害剤を含む真空採血管
Snipsøyr et al. Towards identification of novel putative biomarkers for infective endocarditis by serum proteomic analysis
KR102869359B1 (ko) 기능성 c1 에스테라제 저해제(fc1-inh)의 정량 방법
CN113287019A (zh) 亚临床动脉粥样硬化的生物标志物
HK40129146A (en) Peptide quantitation assay for differentiating full-length high molecular weight kininogen (hmwk) and cleaved hmwk
BR112018012165B1 (pt) Método para detectar cininogênio de alto peso molecular (hmwk) clivado, método para diferenciar hmwk completo e hmwk clivado, e método para identificar um sujeito com, ou correndo o risco de ter, angioedema hereditário (hae)
US20240377410A1 (en) Methods for the measurement of protein c and activated protein c
WO2011049442A2 (en) Blood coagulation status measurement in saliva
Nika et al. Supplemental Information Constitutively Active Lck Kinase in T Cells Drives Antigen Receptor Signal Transduction
EA040036B1 (ru) Вакуумные пробирки для сбора крови, содержащие ингибиторы протеазы, для оценки активации контактной системы

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20180712

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20210309

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20211214

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230810

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20240805

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20241105

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20241106

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20241107

End annual number: 3

Start annual number: 1

PG1601 Publication of registration